Study details
Enrolling now
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
SeaStar Medical
NCT IDNCT05758077ClinicalTrials.gov data as of Apr 2026
Target enrollment
200
Study length
about 4.2 years
Ages
18+
Locations
33 sites in AL, AR, CA +17
What this study is about
Researchers are testing whether up to ten treatments with a Selective Cytopheretic Device (SCD) will improve survival in people with Acute Kidney Injury (AKI) who need continuous kidney replacement therapy (CKRT), compared to CKRT alone. The trial also aims to see if SCD therapy can shorten the time needed for maintenance dialysis after AKI.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Standard of Care
- 2.Use Selective Cytopheretic Device
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Renal